FDA Label for Anticoagulant Citrate Dextrose A

View Indications, Usage & Precautions

Anticoagulant Citrate Dextrose A Product Label

The following document was submitted to the FDA by the labeler of this product Citra Labs Llc. The document includes published materials associated whith this product with the essential scientific information about this product as well as other prescribing information. Product labels may durg indications and usage, generic names, contraindications, active ingredients, strength dosage, routes of administration, appearance, warnings, inactive ingredients, etc.

Clinical Pharmacology



ACD-A acts as an anticoagulant by the action of the citrate ion chelating free ionized calcium, thus making calcium unavailable to the coagulation system.


Indications And Usage



Anticoagulant Citrate Dextrose Solution, Solution A, U.S.P. (ACD-A), is intended for use as an anticoagulant in the extracorporeal blood processing with Autologous PRP Systems in production of platelet rich plasma (PRP). Refer to the manufacturer's Operator's Manual of the Autologous PRP System for the Directions for Use.


Contraindications



NOT FOR DIRECT INTRAVENOUS INFUSION


Warnings



NOT FOR DIRECT INTRAVENOUS INFUSION


General



  • Aseptic technique must be maintained at all times.
  • ACD-A solution is a clear and colorless solution. If the product shows any cloudiness or turbidity, the product should be discarded.
  • The closure system provides a biological barrier and should be intact – discard product if system is compromised.

Information For Patients



None.


Carcinogenesis, Mutagenesis, Impairment Of Fertility



Long-term studies in animals have not been performed to evaluate the carcinogenic potential of ACD-A.


Pregnancy



Long-term studies in animals have not been performed to evaluate the effects of ACD- A on pregnant women.


Pediatric Use



The safety and effectiveness of ACD-A in children have not been established.


Adverse Reactions



Not applicable. This product is used as an anticoagulant in the extracorporeal blood processing with Autologous PRP Systems in production of platelet rich plasma (PRP).


Overdosage



Not applicable. This product is used as an anticoagulant in the extracorporeal blood processing with Autologous PRP systems in production of platelet rich plasma (PRP).


Dosage And Administration



Refer to the manufacturer's Operator's Manual of the Autologous PRP System for the Directions for Use.


Rx Only



Caution: Federal Law (US) restricts this devise to sale by or on the order of a Physician.


How Supplied



Anticoagulant Citrate Dextrose Solution, Solution A, U.S.P., (ACD-A)

 REFSIZECASE
 PN 9350-1030 mL10 Vials/Case
 PN 9350-2530 mL25 Vials/Case

Storage And Handling



It is recommended that the product be stored at ambient room temperature, 24 °C (75 °F); however, the product can be stored between 15 °C (59 °F) and 30 °C (86 °F). Protect from freezing and exposure to excessive heat should be minimized.


Other



Manufactured & Distributed by:
CitraLabs™
55 Messina Drive, Braintree, MA 02184
Phone Number: 1-800-299-3411

Authorized Representative:
Biomet U.K. Ltd.
Waterton Industrial Estate
Bridgend, South Wales, CF31 3XA
Great Britain
United Kingdom
Phone 441.65.66.55.221


* Please review the disclaimer below.